Pathogen-Based Therapy — Bacteria Adapted from
▸ Click on the following categories to expand treatment regimens.
▸ Staphylococcus epidermidis
▸ Methicillin-resistant S. aureus
▸ Streptococcus groups A, B, C, G
|
Staphylococcus epidermidis
|
Preferred Regimen
|
▸ Vancomycin 15 mg/kg IV q12h
|
Alternative Regimen
|
▸ TMP-SMX OR
|
|
Methicillin-resistant S. aureus
|
Preferred Regimen
|
▸ Vancomycin 15 mg/kg IV q12h
|
Alternative Regimen
|
▸ TMP-SMX OR Doxycycline' OR Linezolid
|
| {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table21" style="background: #FFFFFF;"
|
|
Staphylococcus aureus, Methicillin sensitive
|
Preferred Regimen
|
▸ Nafcillin 1.5—2 g IV q4h OR ▸ Oxacillin 1.5—2 g IV q4h
|
Alternative Regimen
|
▸ Vancomycin 15 mg/kg IV q6h (trough 15—20 μg/mL) OR ▸ Linezolid 600 mg IV q12h OR ▸ Daptomycin 6 mg/kg IV q24h
|
Staphylococcus aureus, Methicillin resistant
|
Preferred Regimen
|
▸ Vancomycin 15 mg/kg IV q6h (trough 15—20 μg/mL)
|
PLUS
|
▸ Rifampin 600 mg IV q24h
|
Alternative Regimen
|
▸ TMP/SMZ 5 mg/kg IV q6—12h (TMP component) OR ▸ Linezolid 600 mg IV q12h OR ▸ Daptomycin 6 mg/kg IV q24h
|
PLUS
|
▸ Rifampin 600 mg IV q24h
|
|
Staphylococcus epidermidis
|
Preferred Regimen
|
▸ Vancomycin 15 mg/kg IV q6h (trough 15—20 μg/mL)
|
PLUS
|
▸ Rifampin 600 mg IV q24h
|
Alternative Regimen
|
▸ Linezolid 600 mg IV q12h
|
PLUS
|
▸ Rifampin 600 mg IV q24h
|
|
S. pneumoniae, Penicillin MIC ≤0.06 μg/mL
|
Preferred Regimen
|
▸ Penicillin G 4 MU IV q4h OR ▸ Ampicillin 2 g IV q4h
|
Alternative Regimen
|
▸ Cefotaxime 2 g IV q4—6h OR ▸ Ceftriaxone 2 g IV q12h OR ▸ Chloramphenicol 1—1.5 g IV q6h
|
S. pneumoniae, Penicillin MIC ≥0.12 μg/mL, Cefotaxime/Ceftriaxone MIC <1.0 μg/mL
|
Preferred Regimen
|
▸ Cefotaxime 2 g IV q4—6h OR ▸ Ceftriaxone 2 g IV q12h
|
Alternative Regimen
|
▸ Cefepime 2 g IV q8h OR ▸ Meropenem 2 g IV q8h
|
S. pneumoniae, Penicillin MIC ≥0.12 μg/mL, Cefotaxime/Ceftriaxone MIC ≥1.0 μg/mL
|
Preferred Regimen
|
▸ Vancomycin 15 mg/kg IV q6h (trough 15—20 μg/mL)
|
PLUS
|
▸ Cefotaxime 2 g IV q4—6h OR ▸ Ceftriaxone 2 g IV q12h
|
PLUS
|
▸ Rifampin 600 mg IV q24h
|
Alternative Regimen
|
▸ Vancomycin 15 mg/kg IV q6h (trough 15—20 μg/mL)
|
PLUS
|
▸ Moxifloxacin 400 mg IV q24h
|
|
Mycobacterium tuberculosis (New Patients)
|
Intensive Phase
|
▸ Isoniazid 5 mg/kg PO qd × 2 months OR ▸ Isoniazid 10 mg/kg PO 3 times per week × 2 months
|
PLUS
|
▸ Rifampicin 10 mg/kg PO qd × 2 months OR ▸ Rifampicin 10 mg/kg PO 3 times per week × 2 months
|
PLUS
|
▸ Pyrazinamide 25 mg/kg PO qd × 2 months OR ▸ Pyrazinamide 35 mg/kg PO 3 times per week × 2 months
|
PLUS
|
▸ Streptomycin 15 mg/kg PO qd × 2 months OR ▸ Streptomycin 15 mg/kg PO 3 times per week × 2 months
|
Continuation Phase
|
▸ Isoniazid 5 mg/kg PO qd × 4 months OR ▸ Isoniazid 10 mg/kg PO 3 times per week × 2 months
|
PLUS
|
▸ Rifampicin 10 mg/kg PO qd × 4 months OR ▸ Rifampicin 10 mg/kg PO 3 times per week × 2 months
|
Adapted from Treatment of Tuberculosis: Guidelines.[1]
|
|
Borrelia burgdorferi
|
Preferred Regimen
|
▸ Ceftriaxone 2 g IV q24h × 10—28 days
|
Alternative Regimen
|
▸ Cefotaxime 2 g IV q8h × 10—28 days OR ▸ Penicillin G 3—4 MU IV q4h × 10—28 days OR ▸ Doxycycline 100—200 mg PO q12h × 10—28 days
|
Adapted from Clin Infect Dis. 2006;43(9):1089-134.[2]
|
|
Treponema pallidum
|
Preferred Regimen
|
▸ Penicillin G 3—4 MU IV q4h × 10—14 days
|
Alternative Regimen
|
▸ Procaine penicillin 2.4 MU IM q24h × 10—14 days
|
PLUS
|
▸ Probenecid 500 mg PO q6h × 10—14 days
|
Adapted from MMWR Recomm Rep. 2006;55(RR-11):1-94.[3]
|
|
|}
- ↑ Treatment of tuberculosis : guidelin. Geneva: World Health Organization. 2010. ISBN 978-92-4-154783-3.
- ↑ Wormser, GP.; Dattwyler, RJ.; Shapiro, ED.; Halperin, JJ.; Steere, AC.; Klempner, MS.; Krause, PJ.; Bakken, JS.; Strle, F. (2006). "The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America". Clin Infect Dis. 43 (9): 1089–134. doi:10.1086/508667. PMID 17029130.
- ↑ Workowski, KA.; Berman, SM. (2006). "Sexually transmitted diseases treatment guidelines, 2006". MMWR Recomm Rep. 55 (RR-11): 1–94. PMID 16888612.